27988342|t|Prognostic factors in patients with spinal metastasis: a systematic review and meta-analysis
27988342|a|Incidence of symptomatic spinal metastasis has increased owing to improvement in treatment of the disease. One of the key factors that influences decision-making is expected patient survival. To our knowledge, no systematic reviews or meta-analysis have been conducted that review independent prognostic factors in spinal metastases. This study aimed to determine independent prognostic factors that affect outcome in patients with metastatic spine disease. This is a systematic literature review and meta-analysis of publications for prognostic factors in spinal metastatic disease. Pooled patient results from cohort and observational studies. Meta-analysis for poor prognostic factors as determined by hazard ratio (HR) and 95% confidential interval (95% CI). We systematically searched relevant publications in PubMed and Embase. The following search terms were used: ("' spinal metastases '" OR "' vertebral metastases '" OR " spinal metastasis " OR ' vertebral metastases ') AND ('" prognostic factors "' OR "' survival '"). Inclusion criteria were prospective and retrospective cohort series that report HR and 95% CI of independent prognostic factors from multivariate analysis. Two reviewers independently assessed all papers. The quality of included papers was assessed by using Newcastle-Ottawa Scale for cohort studies and publication bias was assessed by using funnel plot, Begg test, and Egger test. The prognostic factors that were mentioned in at least three publications were pooled. Meta-analysis was performed using HR and 95% CI as the primary outcomes of interest. Heterogeneity was assessed using the I(2) method. A total of 3,959 abstracts (1,382 from PubMed and 2,577 from Embase) were identified through database search and 40 publications were identified through review of cited publications. The reviewers selected a total of 51 studies for qualitative synthesis and 43 studies for meta-analysis. Seventeen poor prognostic factors were identified. These included presence of a neurologic deficit before surgery, non-ambulatory status before radiotherapy (RT), non-ambulatory status before surgery, presence of bone metastases, presence of multiple bone metastases (>2 sites), presence of multiple spinal metastases (>3 sites), development of motor deficit in <7 days before initiating RT, development of motor deficit in <14 days before initiating RT, time interval from cancer diagnosis to RT <15 months, Karnofsky Performance Score (KPS) 10-40, KPS 50-70, KPS <70, Eastern Cooperative Oncology Group (ECOG) grade 3-4, male gender, presence of visceral metastases, moderate growth tumor on Tomita score (TS) classification, and rapid growth tumor on TS classification. Seventeen independent poor prognostic factors were identified in this study. These can be categorized into cancer - specific and nonspecific prognostic factors. A tumor -based prognostic scoring system that combines all specific and general factors may enhance the accuracy of survival prediction in patients with metastatic spine disease.
27988342	0	18	Prognostic factors	T201	C1514474
27988342	22	30	patients	T101	C0030705
27988342	36	53	spinal metastasis	T191	C0347016
27988342	57	74	systematic review	T170	C1955832
27988342	79	92	meta-analysis	T062	C0920317
27988342	93	102	Incidence	T169	C0220856
27988342	106	117	symptomatic	T169	C0231220
27988342	118	135	spinal metastasis	T191	C0347016
27988342	140	149	increased	T081	C0205217
27988342	159	170	improvement	T077	C2986411
27988342	174	183	treatment	T169	C1522326
27988342	191	198	disease	T047	C0012634
27988342	215	222	factors	T169	C1521761
27988342	228	238	influences	T077	C4054723
27988342	239	254	decision-making	T041	C0011109
27988342	267	274	patient	T101	C0030705
27988342	275	283	survival	T169	C0220921
27988342	306	324	systematic reviews	T170	C1955832
27988342	328	341	meta-analysis	T062	C0920317
27988342	367	373	review	T169	C0699752
27988342	374	385	independent	T078	C0085862
27988342	386	404	prognostic factors	T201	C1514474
27988342	408	425	spinal metastases	T191	C0347016
27988342	432	437	study	T062	C0008972
27988342	457	468	independent	T078	C0085862
27988342	469	487	prognostic factors	T201	C1514474
27988342	500	507	outcome	T080	C0085415
27988342	511	519	patients	T101	C0030705
27988342	525	549	metastatic spine disease	T191	C0347016
27988342	561	571	systematic	T169	C0220922
27988342	572	589	literature review	T170	C0282441
27988342	594	607	meta-analysis	T062	C0920317
27988342	628	646	prognostic factors	T201	C1514474
27988342	650	675	spinal metastatic disease	T191	C0347016
27988342	677	683	Pooled	T169	C2349200
27988342	684	691	patient	T101	C0030705
27988342	705	711	cohort	T081	C0009247
27988342	716	737	observational studies	T062	C1518527
27988342	739	752	Meta-analysis	T062	C0920317
27988342	762	780	prognostic factors	T201	C1514474
27988342	798	810	hazard ratio	T081	C2985465
27988342	812	814	HR	T081	C2985465
27988342	824	845	confidential interval	T081	C0009667
27988342	851	853	CI	T081	C0009667
27988342	859	873	systematically	T169	C0220922
27988342	883	891	relevant	T080	C2347946
27988342	892	904	publications	T073,T170	C0034036
27988342	908	914	PubMed	T170	C1138432
27988342	919	925	Embase	T170	C0282574
27988342	969	986	spinal metastases	T191	C0347016
27988342	996	1016	vertebral metastases	T191	C0347016
27988342	1025	1042	spinal metastasis	T191	C0347016
27988342	1050	1070	vertebral metastases	T191	C0347016
27988342	1082	1100	prognostic factors	T201	C1514474
27988342	1110	1118	survival	T169	C0220921
27988342	1124	1142	Inclusion criteria	T080	C1512693
27988342	1148	1159	prospective	T080	C0205556
27988342	1164	1177	retrospective	T080	C1514923
27988342	1178	1191	cohort series	T081	C0009247
27988342	1204	1206	HR	T081	C2985465
27988342	1215	1217	CI	T081	C0009667
27988342	1221	1232	independent	T078	C0085862
27988342	1233	1251	prognostic factors	T201	C1514474
27988342	1257	1278	multivariate analysis	T081	C0026777
27988342	1284	1293	reviewers	T098	C1882950
27988342	1294	1307	independently	T078	C0085862
27988342	1308	1316	assessed	T052	C1516048
27988342	1333	1340	quality	T080	C0332306
27988342	1364	1372	assessed	T052	C1516048
27988342	1382	1404	Newcastle-Ottawa Scale	T170	C0282574
27988342	1409	1423	cohort studies	T081	C0009247
27988342	1428	1439	publication	T073,T170	C0034036
27988342	1440	1444	bias	T078	C0242568
27988342	1449	1457	assessed	T052	C1516048
27988342	1467	1478	funnel plot	T170	C0237913
27988342	1480	1489	Begg test	T170	C0237913
27988342	1495	1505	Egger test	T170	C0237913
27988342	1511	1529	prognostic factors	T201	C1514474
27988342	1568	1580	publications	T073,T170	C0034036
27988342	1586	1592	pooled	T169	C2349200
27988342	1594	1607	Meta-analysis	T062	C0920317
27988342	1628	1630	HR	T081	C2985465
27988342	1639	1641	CI	T081	C0009667
27988342	1657	1665	outcomes	T169	C1274040
27988342	1679	1692	Heterogeneity	T080	C0019409
27988342	1697	1705	assessed	T052	C1516048
27988342	1716	1727	I(2) method	T062	C0242481
27988342	1746	1755	abstracts	T170	C0600678
27988342	1768	1774	PubMed	T170	C1138432
27988342	1790	1796	Embase	T170	C0282574
27988342	1803	1813	identified	T080	C0205396
27988342	1822	1830	database	T170	C0242356
27988342	1845	1857	publications	T073,T170	C0034036
27988342	1863	1873	identified	T080	C0205396
27988342	1882	1888	review	T169	C0699752
27988342	1898	1910	publications	T073,T170	C0034036
27988342	1916	1925	reviewers	T098	C1882950
27988342	1961	1972	qualitative	T080	C0205556
27988342	1973	1982	synthesis	T052	C1883254
27988342	2002	2015	meta-analysis	T062	C0920317
27988342	2032	2050	prognostic factors	T201	C1514474
27988342	2056	2066	identified	T080	C0205396
27988342	2083	2091	presence	T033	C0150312
27988342	2097	2115	neurologic deficit	T033	C0521654
27988342	2123	2130	surgery	T091	C1274039
27988342	2132	2146	non-ambulatory	T033	C0560046
27988342	2147	2153	status	T080	C0449438
27988342	2161	2173	radiotherapy	T061	C0085203
27988342	2175	2177	RT	T061	C0085203
27988342	2180	2194	non-ambulatory	T033	C0560046
27988342	2195	2201	status	T080	C0449438
27988342	2209	2216	surgery	T091	C1274039
27988342	2218	2226	presence	T033	C0150312
27988342	2230	2245	bone metastases	T191	C0153690
27988342	2247	2255	presence	T033	C0150312
27988342	2259	2267	multiple	T081	C0439064
27988342	2268	2283	bone metastases	T191	C0153690
27988342	2288	2293	sites	T029	C1515974
27988342	2296	2304	presence	T033	C0150312
27988342	2308	2316	multiple	T081	C0439064
27988342	2339	2344	sites	T029	C1515974
27988342	2347	2358	development	T039	C0243107
27988342	2362	2375	motor deficit	T033	C0521654
27988342	2382	2386	days	T079	C0439228
27988342	2405	2407	RT	T061	C0085203
27988342	2409	2420	development	T039	C0243107
27988342	2424	2437	motor deficit	T033	C0521654
27988342	2445	2449	days	T079	C0439228
27988342	2468	2470	RT	T061	C0085203
27988342	2472	2485	time interval	T079	C0872291
27988342	2491	2507	cancer diagnosis	T060	C0920688
27988342	2511	2513	RT	T061	C0085203
27988342	2518	2524	months	T079	C0439231
27988342	2526	2553	Karnofsky Performance Score	T170	C0282574
27988342	2555	2558	KPS	T170	C0282574
27988342	2567	2570	KPS	T170	C0282574
27988342	2578	2581	KPS	T170	C0282574
27988342	2587	2621	Eastern Cooperative Oncology Group	T093	C1512162
27988342	2623	2627	ECOG	T093	C1512162
27988342	2629	2638	grade 3-4	T185	C0441800
27988342	2640	2651	male gender	T032	C0086582
27988342	2653	2661	presence	T033	C0150312
27988342	2665	2673	visceral	T082	C0442045
27988342	2674	2684	metastases	T191	C0027627
27988342	2686	2694	moderate	T080	C0205081
27988342	2695	2701	growth	T040	C0018270
27988342	2702	2707	tumor	T191	C0027651
27988342	2711	2743	Tomita score (TS) classification	T170	C0282574
27988342	2749	2754	rapid	T080	C0456962
27988342	2755	2761	growth	T040	C0018270
27988342	2762	2767	tumor	T191	C0027651
27988342	2771	2788	TS classification	T170	C0282574
27988342	2800	2811	independent	T078	C0085862
27988342	2812	2816	poor	T080	C0542537
27988342	2817	2835	prognostic factors	T201	C1514474
27988342	2841	2851	identified	T080	C0205396
27988342	2860	2865	study	T062	C0008972
27988342	2880	2891	categorized	T052	C0871968
27988342	2897	2903	cancer	T191	C0006826
27988342	2906	2914	specific	T080	C0205369
27988342	2919	2930	nonspecific	T078	C0750540
27988342	2931	2949	prognostic factors	T201	C1514474
27988342	2953	2958	tumor	T191	C0027651
27988342	2966	2991	prognostic scoring system	T170	C0282574
27988342	3010	3018	specific	T080	C0205369
27988342	3031	3038	factors	T169	C1521761
27988342	3043	3050	enhance	T052	C2349975
27988342	3055	3063	accuracy	T080	C0443131
27988342	3067	3075	survival	T169	C0220921
27988342	3076	3086	prediction	T078	C0681842
27988342	3090	3098	patients	T101	C0030705
27988342	3104	3128	metastatic spine disease	T191	C0347016